domingo, 18 de septiembre de 2016

Inactivation of Cancer Mutations Utilizing CRISPR/Cas9. - PubMed - NCBI

Inactivation of Cancer Mutations Utilizing CRISPR/Cas9. - PubMed - NCBI



 2016 Aug 30;109(1). pii: djw183. doi: 10.1093/jnci/djw183. Print 2017 Jan.

Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.

Abstract

Although whole-genome sequencing has uncovered a large number of mutations that drive tumorigenesis, functional ratification for most mutations remains sparse. Here, we present an approach to test functional relevance of tumor mutations employing CRISPR/Cas9. Combining comprehensive sgRNA design and an efficient reporter assay to nominate efficient and selective sgRNAs, we establish a pipeline to dissect roles of cancer mutations with potential applicability to personalized medicine and future therapeutic use.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PMID:
 
27576906
 
DOI:
 
10.1093/jnci/djw183

[PubMed - in process]

No hay comentarios:

Publicar un comentario